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Proteomic Technologies
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Stoichiometry of Site-Specific Protein
Phosphorylation Estimated with
Phosphopeptide-Specific Antibodies
BioTechniques 34:828-831 (April 2003)

Cristinel P. Mîinea and
Gustav E. Lienhard
Dartmouth Medical School,
Hanover, NH, USA
In recent years, antibodies specific
for phosphopeptides have become a
major tool for assessing the phosphorylation of specific serine, threonine, and
tyrosine sites on proteins (1,2). Typically, a phosphopeptide-specific antibody
is used for the qualitative detection of
phosphorylation at a site through immunoblotting the protein of interest.
Here we describe a relatively simple
method by which a phosphopeptidespecific antibody can be used to estimate the stoichiometry of phosphorylation at its corresponding site. By
contrast, other methods for the estimation of the stoichiometry of phosphorylation at a site are considerably more
demanding and complicated (3).
The stoichiometry of phosphorylation at a particular site is defined as
Pt*/Pt, where Pt* is the total moles of
protein phosphorylated on the site and
Pt is the total moles of protein. To determine this ratio, the phosphopeptidespecific antibody is used to immunoprecipitate only the phosphorylated
form of the protein. The overall efficiency of immunoprecipitation of the
protein is measured by immunoblotting
aliquots of the starting solution and the
immunoprecipitate with an antibody
against a nonphosphorylated epitope in
the protein and comparing the signals
of the latter with those of the former.
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This efficiency is P*p/Pt, where P*p is
the moles of immunoprecipitated phosphorylated protein. If all the phosphorylated form of the protein were immunoprecipitated, then P*p would
equal P*t, and the stoichiometry of
phosphorylation would be equal to the
overall efficiency of immunoprecipitation. However, usually only a fraction
of the phosphorylated form is immunoprecipitated, and, consequently, a correction must be made. To do so, the efficiency of immunoprecipitation of
only the phosphorylated protein is measured by immunoblotting aliquots of
the starting solution and the immunoprecipitate with the phosphopeptidespecific antibody and comparing the
signals of the latter with those of the
former. This efficiency is P*p/P*t.
Thus, the stoichiometry of phosphorylation (P*t/Pt) is equal to the ratio of
the overall efficiency of immunoprecipitation (P*p/Pt) to the efficiency of
immunoprecipitation of the phosphorylated form (P*p/P*t).
The protein is prepared for the immunoprecipitation with the phosphopeptide-specific antibody by denaturation with SDS and reduction with
dithiothreitol. This procedure should
expose the phosphopeptide site in the
protein for reaction with the antibody.
In addition, if the native protein exists
as an oligomer, it converts it into the individual subunits, and thus the nonphosphorylated subunits do not coimmunoprecipitate with phosphorylated
ones. The immunoprecipitation is performed after addition of sufficient nonionic detergent to incorporate the SDS

into micelles so that the antibody is not
denatured. A useful modification of the
method would be to cap the sulfhydryl
groups with N-ethylmaleimide to ensure that no disulfide bonds reform.
This was not done in the present study
because the protein examined contains
a cysteine two residues from a phosphorylation site.
As an example of this method, we
examined the phosphorylation of the
serine kinase Akt1 on two sites, Thr 308
and Ser 473. Phosphorylation of these
sites results in activation of this kinase
(4). The required reagents were purchased as follows: active and inactive
recombinant Akt1 (Upstate, Charlottesville, VA, USA); antibodies against the
Akt1 phospho Thr 308 and phospho Ser
473 peptides (Cell Signaling Technology, Beverly, MA, USA); and a monoclonal antibody against the nonphosphorylated PH domain of Akt1 (Upstate).
Stock solutions of 500 ng/mL Akt1
were prepared in 2% SDS, 10 mM
dithiothreitol, 150 mM NaCl, 50 mM
HEPES, pH 7.4, with 1 mg/mL ovalbumin as carrier, and held at 100°C for 5
min. For immunoprecipitations, 200 µL
of this solution were mixed with 1.125
mL 1.7% nonaethyleneglycol dodecyl
ether (Sigma, St. Louis, MO, USA), 150
mM NaCl, 50 mM HEPES, pH 7.4
(buffer A), and either 1 µg antibody
against phospho Thr 308 or 200 ng antibody against phospho Ser 473 were
added. After 2 h at 4°C, the immune
complexes were collected by mixing for
a further 2 h with 20 µL protein ASepharose. The beads were then
washed four times with buffer A, and
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Table 1. Outline of the Protocol for Estimating the Stoichiometry of Site-Specific Phosphorylation

1.Denature and reduce the isolated protein in 2% SDS/10 mM dithiothreitol at
100°C for 5 min. Cool and cap the thiol groups by the addition of 2.5 moles of
N-ethylmaleimide per mole dithiothreitol. Save an aliquot of this solution (the input solution) to use for immunoblotting.
2.To the remainder, add a sufficient volume of 1.7% nonaethyleneglycol dodecyl
ether, 150 mM NaCl, 50 mM HEPES, pH 7.4 (buffer A), so that the ratio of this
detergent to SDS is at least 3.5 by weight.
3.Immunoprecipitate the protein in buffer A with the phosphospecific antibody.
Adsorb the immune complexes on protein A-Sepharose.
4.Elute the immunoprecipitated protein by suspending the protein A-Sepharose
beads in SDS sample buffer and holding at 100°C for 5 min.
5.Immunoblot samples of the input solution and of the immunoprecipitate with an
antibody against a nonphosphorylated epitope on the protein. Calculate the total efficiency of immunoprecipitation from the relative intensities on the immunoblot and the sample sizes as fractions of the input solution from which
they were derived. Perform a second immunoblot of this type with the phosphopeptide-specific antibody, and calculate the efficiency of immunoprecipitation of
the phosphorylated form in the same way.
6.The estimated stoichiometry of phosphorylation is the ratio of the total efficiency of immunoprecipitation to the efficiency of immunoprecipitation of the phosphorylated form.

the immunoprecipitate was released by
heating with 150 µL SDS sample buffer
(4% SDS, 10% glycerol, 1 mM EDTA,
0.004% bromophenol blue, 90 mM Tris,
pH 6.8) containing 10 mM dithiothreitol

at 100°C for 5 min. Ovalbumin at 100
µg/mL was included as carrier in the
SDS sample buffer used for dilutions.
Samples of the starting solution and
the immunoprecipitates were separated

Figure 1. Immunoprecipitation of Akt1 with the antibody against phospho Thr 308. Aliquots of the
starting solutions of active Akt1 (aAkt) (lanes 1–4) and inactive Akt1 (iAkt) (lanes 5 and 6) and of the
immunoprecipitates of active Akt1 (lanes 7–9) and inactive Akt1 (lanes 10 and 11) with anti-phospho
Thr 308 were immunoblotted with either the antibody against the Akt1 PH domain (upper panel) or the
antibody against phospho Thr 308 (lower panel). Lane 12 contained a control immunoprecipitate in
which active Akt1 was immunoprecipitated with irrelevant rabbit immunoglobulin (IgG). The band due
to the heavy chain of the precipitating antibody is designated hc. For lanes 1–6, the loads of Akt1 in
nanograms are given. For lanes 7–12, in each case, the nanogram given is the amount of Akt1 in the starting solution from which the load of immunoprecipitate was derived. Two repetitions of this experiment
gave values similar to this one for the fraction of active Akt1 phosphorylated on Thr 308.
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by SDS-PAGE and transferred electrophoretically to an Immobilon
membrane (Millipore, Bedford, MA,
USA). The membrane was blocked
with 1% BSA in TBST (20 mM Tris,
pH 7.6, 150 mM NaCl, 0.3% Tween®
20) treated with primary antibodies in
0.5% BSA, TBST for at least 1 h, and
washed with TBST. Primary antibodies
were used at the manufacturer’s recommended concentrations. The membrane was then treated with HRP-protein A conjugate in the case of the
rabbit phosphopeptide antibodies or
HRP-goat anti-mouse immunoglobulin
conjugate in the case of the mouse antibody against the PH domain (Bio-Rad
Laboratories, Hercules, CA, USA).
Detection was with the SuperSignal®
chemiluminescence reagent (Pierce
Chemical, Rockford, IL, USA) and autoradiography. Each immunoblot contained four amounts (1×, 1/2×, 1/4×,
and 1/8×) of the starting solution of
Akt1, which were chosen so that their
signals bracketed one or more signals
given by aliquots of the immunoprecipitate. The amount of Akt1 in each
immunoprecipitate sample was estimated by visual comparison of its signal with those given by these standards. In our hands, this method gives
values that are the same as those given
by densitometry of the autoradiograms.
The efficiency of immunoprecipitation
was then calculated from the amount of
Akt1 in the immunoprecipitate and the
amount of Akt1 in the solution from
which the immunoprecipitate was derived. We estimate that the error in the
efficiency measured in this way is no
more than ± 25%. If greater accuracy is
desired, it might be achieved by the use
of a range of more closely spaced input
standards and instrumental quantitation of the blots.
Figure 1 presents the results with the
antibody specific for phospho Thr 308.
The overall efficiency of immunoprecipitation of active Akt1 was approximately 8% (upper panel, compare lanes
7–9 with lanes 1–4 and see the figure
legend), whereas the efficiency of immunoprecipitation of the phosphorylated active Akt1 was approximately 33%
(lower panel, compare lanes 7–9 with
lanes 1–4). Thus, approximately 8/33
or 24% of Thr 308 is phosphorylated in
this preparation of active Akt1. ConVol. 34, No. 4 (2003)

trols showed that inactive Akt1 did not
react with the antibody against phospho
Thr 308, whereas it reacted equally as
well with the antibody against the PH
domain of Akt1 (lanes 5 and 6 of lower
and upper panels, respectively). Also,
the antibody against phospho Thr 308
did not immunoprecipitate inactive
Akt1 (lanes 10 and 11 in both panels),
nor did an irrelevant antibody immunoprecipitate active Akt1 (lane 12).
The same analysis was performed to
determine the stoichiometry of phosphorylation on Ser 473 in Akt1, with
the antibody against the phospho Ser
473 peptide. In this case, with active
Akt1 the overall efficiency of immunoprecipitation and the efficiency of immunoprecipitation of the phosphorylated form were each approximately 33%,
whereas no inactive Akt1 was immunoprecipitated (data not shown). Consequently, approximately 100% of the
Akt1 in this preparation was phosphorylated on Ser 473.
The active Akt1 used here was prepared by phosphorylation of Thr 308
with the kinase PDK1 and Ser 473 with
the kinase MAPKAP2 according to
methods developed by Dr. Dario Alessi
at the University of Dundee and transferred to Upstate. The stoichiometry of
phosphorylation at each site for such
preparations has been estimated from
the incorporation of 32P phosphate
from γ[32P]ATP into known amounts of
Akt, and the values are in the range of
30%–70% (private communication, Dr.
Alessi and Reference 5). Thus, the values here are in reasonable agreement
with the estimates from this alternative
method, when one considers that our
method has the potential for some error
due to some imprecision in the values
for the efficiencies of immunoprecipitation and that the other method relies
on estimates of protein amount, which
can be inaccurate.
In assessing the significance of the
phosphorylation of a protein in vivo at
a particular site, it is useful to have an
estimate of the stoichiometry. This
method should be applicable to a phosphorylated protein in a cell lysate, by
first isolating a representative mixture
of phosphorylated and nonphosphorylated protein. For example, cells could
be lysed in SDS/dithiothreitol and then
the lysate prepared for immunoprecipiVol. 34, No. 4 (2003)

tation with excess nonionic detergent
and N-ethylmaleimide. The mixture of
phosphorylated and non-phosphorylated protein could then be immunoprecipitated with the antibody against the
non-phosphorylated epitope. This immunoprecipitate would then be solubilized in SDS and analyzed as described
in the text and in Table 1, which summarizes the method.
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